Ikena Oncology, Inc.

Founded in 2016 and based in Massachusetts, US, Ikena Oncology, Inc. , formerly known as Kyn Therapeutics, operates as a biotechnology company. The company was co-founded by CEO and President Mark Manfredi, Ph. D.

and Senior VP for Research and Development Michelle Zhang, Ph. D. In January 2021, Ikena Oncology, raised USD 120 in Series B funding led by Omega Funds, with participation from BVF Partners, Cowen Healthcare Investments, and other investors. In March 2021, the company raised USD 125 million in an IPO, selling 7.

81 million shares at USD 16 per share on the Nasdaq. In December 2024, Inmagene Biopharmaceuticals, a portfolio company of BC Capital, Kunlun VC, Panacea Venture, South China Venture Capital, Vertex Ventures China, Calor Capital, Epiphron Capital, HighLight Capital, Triwise Capital, and VMS Group, agreed to merge with Ikena Oncology, Inc. , a portfolio company of Atlas Venture, OrbiMed Advisors, Bristol-Myers Squibb Company, BVF Partners, Cowen Investment Management, Farallon Capital Management, Fidelity Investments, HealthCor Management, Invus, Logos Capital, Omega Funds, Surveyor Capital, Acuta Capital Partners, Adage Capital Management, Vestal Point Capital, Gilead Sciences, Inc. , Mission Bay Capital, New Enterprise Associates, OUP (Osage University Partners), Sofinnova Investments, SV Health Investors, Vida Ventures, and now operates under the name ImageneBio, Inc.

, with a PIPE funding of USD 75 million from Deep Track Capital, Foresite Capital, RTW Investments, BVF Partners, BLUE OWL CREDIT PRIVATE FUND ADVISORS, Omega Funds, and OrbiMed Advisors. The company will be publicly listed on the Nasdaq Global Select Market under the ticker symbol "IMA". Ikena Oncology is a clinical-stage biotechnology company that focuses, discovers, and develops patient-directed, biomarker-driven therapies for cancer patients who need life-saving treatment, by understanding what drives their disease. Ikena is advancing five clinical, preclinical, and discovery programs: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; a lead optimization-stage KRAS signaling program; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist.

Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Ikena Oncology plans to list on the Nasdaq under the symbol IKNA. The combination plans to utilize the January 2025 funding to advance the clinical development of IMG-007 for atopic dermatitis and other inflammatory indications.